Kazumi_Hirose_5.jpg

Katsumi Hirose, B.Sc., M.D., Ph.D.

Radiation Oncologist
Clinic Director, Southern TOHOKU BNCT Research Center

  • Present Title & Affiliation

    • Clinic Director, Southern TOHOKU BNCT Research Center
    • Visiting Senior Lecturer, Hirosaki University Graduate School of Medicine, Japan
  • Education

    • 2004 B.Sc.

      Faculty of Science and Technology (physics and chemistry fields of study), Sophia University, Japan

    • 2009 M.D.

      Hirosaki University School of Medicine, Japan

    • 2009

      Japanese Medical License issued by the Ministry of Health, Labour and Welfare, Japan

    • 2014 Ph.D.

      Hirosaki University Graduate School of Medicine, Japan

  • Certifications

    • Board-certified Radiologist by Japan Radiological Society (JRS)
    • Board-certified Radiation Oncologist by Japanese Society for Radiation Oncology (JASTRO)
  • Professional Experience

    • 2009-2011

      Resident, Hirosaki University Hospital, Japan

    • 2011-2013

      Clinical Fellow, Dept. of Diagnostic Radiology & Dept. of Radiation Oncology, HIrosaki University Hospital, Japan

    • 2013-2015

      Lecturer, Dept. of Radiology and Radiation Oncology, HIrosaki University School of Medicine, Japan

    • 2015-present

      Clinic Director, Southern TOHOKU BNCT Research Center

    • 2015-May 2020

      Visiting Senior Lecturer, Hirosaki University Graduate School of Medicine, Japan

    • June 2020-present

      Visiting Associate Professor, Hirosaki University Graduate School of Medicine, Japan

  • Skill Highlights

    • Boron Neutron Capture Therapy (BNCT)
    • Radiation oncology
    • Radiation biology
  • Honors & Awards

    • 2011

      Best Resident Award, Hirosaki University School of Medicine and University Hospital, Japan

    • 2012-2014

      Grant-in-Aid for Young Scientists (B) supported by the Japan Society for the Promotion of Science (JSPS). JSPS No.24791266, 2012-2014 (JPY 4,270,000)

    • 2014-2016

      Grant-in-Aid for Young Scientists (B) supported by the Japan Society for the Promotion of Science (JSPS). JSPS No.2686967, 2014-2016 (JPY 3,770,000)

  • Selected Publications

    • Hirose, K., Sato, M., Aoki, M., et al. How Can We Overcome Radiation Induced Recruitment of Cancer Stem Cells Under Chronic Hypoxia: Contribution of Fraction Dose Size As a Key Factor. International Journal of Radiation Oncology* Biology* Physics (57th ASTRO Annual Meeting). 2015, 93(3): E536
    • Hirose, K., Sato, M., Kawaguchi, H., et al. Dosimetric Impact of Positioning Error Due to Temporarily Indwelled Urethral Catheter for Planning CT in Urethra-Sparing Prostate IMRT. International Journal of Radiation Oncology* Biology* Physics (57th ASTRO Annual Meeting). 2015, 93(3): E23
    • Hirose, K., Sato, M., Aoki, M., et al. SU-EJ-40: Improving Uncertainty of Prostate Positioning by Using Implanted Fiducial Marker-Based Hybrid Evaluation Combined with KV Portal Imaging and CBCT for Prostate IMRT. Medical physics (57th AAPM Annual Meeting). 2015, 42(6): 3272-3272
    • Aoki, M., Sato, M., Hirose, K., et al. Radiation-induced rib fracture after stereotactic body radiotherapy with a total dose of 54–56 Gy given in 9–7 fractions for patients with peripheral lung tumor: impact of maximum dose and fraction size. Radiation Oncology. 2015, 10(1): 99
    • Sato, M., Hirose, K.*, Kashiwakura, I., et al. LW6, a hypoxia‑inducible factor 1 inhibitor, selectively induces apoptosis in hypoxic cells through depolarization of mitochondria in A549 human lung cancer cells. Molecular medicine reports. 2015, 3462-3468
    • Hirose, K., Monzen, S., Yoshino, H., et al. Effects of radiation on the maturation of megakaryocytes. Journal of radiation research. 2013, 54(3): 447-45
    • Hirose, K., Monzen, S., Sato, H., et al. Megakaryocytic differentiation in human chronic myelogenous leukemia K562 cells induced by ionizing radiation in combination with phorbol 12-myristate 13-acetate. Journal of radiation research. 2013, 54(3): 438-44
    • Ishiguro A., Takahata T., Hirose K., et al. [A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)]. Gan To Kagaku Ryoho. 2010 Aug;37(8):1579-82. In Japanese
Printer Friendly